TL;DR: In a prospective study of a cohort of intravenous drug abusers in New York City who tested positive with the tuberculin skin test, the risk of active tuberculosis was 14 per cent (seven of fortynine patients) a year during a two-year follow-up interval.
Abstract: The prevalence of tuberculosis15 in the United States has been rising since 1986, with morbidity increasing 14 per cent from 1985 through 1993. In 1986, the rate of tuberculosis in the United States was 9.3 new cases per 100,000 population. In 1991, the rate in New York State12,13 had risen to 17.3 per 100,000, and the rate in central Harlem was 169 per 100,000, which is similar to rates reported in the eastern and central regions of Africa7,12. Much of this increase has been in the rate of pulmonary tuberculosis, but it has been associated with a concomitant rise in the number of adults and children who have tubercular musculoskeletal involvement. In a prospective study of a cohort of intravenous drug abusers in New York City who tested positive with the tuberculin skin test, the risk of active tuberculosis was 14 per cent (seven of forty-nine patients) a year during a two-year follow-up interval76. It is becoming increasingly likely that an orthopaedic surgeon who works in a developed region of the world (especially in a big city) will encounter a patient who has tuberculosis, a disease with which the surgeon may have little experience or training13.
Factors that have contributed to the increased rate of tuberculosis are the rise in the number of people who have suppression of the immune system, the development of drug-resistant strains of Mycobacterium, an aging population, and an increase in the number of health-care workers who are exposed to the disease. The human immunodeficiency virus remains the leading known risk factor for the reactivation of latent tuberculous infection65,68,79, and patients with this virus who are exposed to Mycobacterium tuberculosum are more likely to have progression to an …
TL;DR: Skeletal tuberculosis occurs in approximately 1 per cent of patients with tuberculosis and early diagnosis is essential since excellent therapy is available and far advanced destruction and long suffering and disability can be avoided.
TL;DR: Due to its ideal pharmacologic action and cytocompatibility, the programmed release multi-drug implant with a complex construction fabricated by 3D printing technology could be of interest in prevention and treatment of bone tuberculosis.
Abstract: In the world, bone tuberculosis is still very difficult to treat and presents a challenge to clinicians. In this study, we utilized 3D printing technology to fabricate a programmed release multi-drug implant for bone tuberculosis therapy. The construction of the drug implant was a multi-layered concentric cylinder divided into four layers from the center to the periphery. Isoniazid and rifampicin were distributed individually into the different layers in a specific sequence of isoniazid-rifampicin-isoniazid-rifampicin. The drug release assays in vitro and in vivo showed that isoniazid and rifampicin were released orderly from the outside to the center to form the multi-drug therapeutic alliance, and the peak concentrations of drugs were detected in sequence at 8 to 12 day intervals. In addition, no negative effect on the proliferation of rabbit bone marrow mesenchymal stem cells was detected during the cytocompatibility assay. Due to its ideal pharmacologic action and cytocompatibility, the programmed release multi-drug implant with a complex construction fabricated by 3D printing technology could be of interest in prevention and treatment of bone tuberculosis.
TL;DR: It is demonstrated the composite system can simultaneously achieve localized long-term drug controlled release and bone regeneration, which provides a promising route for improved bone TB treatment.